Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“Receiving Saudi FDA approval is an important step in our commercial expansion across the Middle East. Saudi Arabia represents the largest healthcare market in the region, and this approval enables eligible patients to access our technology through the national reimbursement system without personal financial burden.

We also see significant potential for Saudi Arabia to serve as a regional referral hub, with patients from across the Gulf and the broader Middle East travelling to leading Saudi hospitals for advanced cancer treatment.”